Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

BIOLIFE SOLUTIONS INC
Next earnings Aug 5, 2026 · consensus $0.03 EPS, $28.1M rev
Last earnings +6.3% on 2026-05-07
Revenue grew 28.9% YoY; but unprofitable (net margin -4.8%).
BIOLIFE SOLUTIONS INC shows $96.2M in FY2025 revenue (+28.9% YoY), a -4.8% net margin, and -1.2% ROE.
Sources: SEC EDGAR (CIK 0000834365, latest 10-Q filed 2026-05-07) · EODHD · as of 6/22/2026, 1:50:35 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $119M | $76.2M | $68.0M | $74.6M | $96.2M |
| Gross profit | — | — | $41.3M | $50.1M | $62.1M |
| Operating income | -$35.2M | -$5.92M | -$17.2M | -$4.48M | -$16.6M |
| Net income | -$8.91M | -$140M | -$68.0M | -$20.2M | -$4.59M |
| Diluted EPS | -$0.23 | -$3.25 | -$1.55 | -$0.44 | -$0.10 |
| Net margin | -7.5% | -183.4% | -100.0% | -27.0% | -4.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Last 90 days: 0 open-market buys · 3 sales
| 2026-06-08 | Wichterman Troy Chief Financial Officer | Tax | 1.03K @ $26.10 | $26.8K |
| 2026-06-08 | Berard Todd Chief Marketing Officer | Tax | 356.00 @ $26.10 | $9.29K |
| 2026-06-08 | Mathew Aby J. EVP & Chief Scientific Officer | Tax | 627.00 @ $26.10 | $16.4K |
| 2026-05-21 | Casdin Partners Master Fund, L.P. 10% owner | Sell | 650K @ $23.70 | $15.4M |
| 2026-05-20 | Casdin Partners Master Fund, L.P. 10% owner | Sell | 250K @ $23.70 | $5.92M |
| 2026-05-19 | Casdin Partners Master Fund, L.P. 10% owner | Sell | 300K @ $22.65 | $6.79M |
| 2026-04-08 | Mathew Aby J. EVP & Chief Scientific Officer | Tax | 515.00 @ $19.27 | $9.92K |
| 2026-04-08 | Berard Todd Chief Marketing Officer | Tax | 293.00 @ $19.27 | $5.65K |
| 2026-04-08 | Wichterman Troy Chief Financial Officer | Tax | 844.00 @ $19.27 | $16.3K |
| 2026-03-23 | Foster Karen A. Chief Quality and Operations | Sell | 2.58K @ $19.17 | $49.4K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.